OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Allergy and Clinical Immunology is 70. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group	471
Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19	293
Coronavirus disease 2019 in patients with inborn errors of immunity: An international study	272
EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management	206
Drug allergy: A 2022 practice parameter update	201
COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience	188
Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council	178
Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial	170
JAK inhibitors in the treatment of atopic dermatitis	167
IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study	166
Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial	164
Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity	155
Food allergy across the globe	153
Heritable risk for severe anaphylaxis associated with increased α-tryptase–encoding germline copy number at TPSAB1	150
New clinical diagnostic criteria for allergic bronchopulmonary aspergillosis/mycosis and its validation	134
Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19	134
Single-cell transcriptomics combined with interstitial fluid proteomics defines cell type–specific immune regulation in atopic dermatitis	133
The sputum microbiome, airway inflammation, and mortality in chronic obstructive pulmonary disease	127
Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study	127
Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis	126
Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines	123
Adult-onset autoinflammation caused by somatic mutations in UBA1: A Dutch case series of patients with VEXAS	120
Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial	118
Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis	116
Asthma-associated risk for COVID-19 development	114

Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon	113
Autoimmune chronic spontaneous urticaria	113
Asthma among hospitalized patients with COVID-19 and related outcomes	109
Regulating T-cell differentiation through the polyamine spermidine	108
Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1	103
Staphylococcus epidermidis protease EcpA can be a deleterious component of the skin microbiome in atopic dermatitis	101
Mechanisms and pathogenesis of chronic rhinosinusitis	99
Advances in asthma: New understandings of asthma’s natural history, risk factors, underlying mechanisms, and clinical management	99
Dietary fiber and SCFAs in the regulation of mucosal immunity	97
Randomized trial of early infant formula introduction to prevent cow’s milk allergy	96
Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach	96
Mechanisms underlying genetic susceptibility to multisystem inflammatory syndrome in children (MIS-C)	95
Health disparities in allergic and immunologic conditions in racial and ethnic underserved populations: A Work Group Report of the AAAAI Committee on the Underserved	93
Climate change and global issues in allergy and immunology	92
The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults	91
Single-cell RNA sequencing of psoriatic skin identifies pathogenic Tc17 cell subsets and reveals distinctions between CD8+ T cells in autoimmunity and cancer	89
COVID-19–associated multisystem inflammatory syndrome in children (MIS-C): A novel disease that mimics toxic shock syndrome—the superantigen hypothesis	87
IL-25 (IL-17E) in epithelial immunology and pathophysiology	86
Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies	86
Clinical Olfactory Working Group consensus statement on the treatment of postinfectious olfactory dysfunction	86
Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial	85
Atopic dermatitis displays stable and dynamic skin transcriptome signatures	84
Severity grading system for acute allergic reactions: A multidisciplinary Delphi study	84
Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study	83
Multifaceted MRGPRX2: New insight into the role of mast cells in health and disease	82
Mas-related G protein–coupled receptor X2 and its activators in dermatologic allergies	80
Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations	80
Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees	79
Compartmental immunophenotyping in COVID-19 ARDS: A case series	79
The HOME Core outcome set for clinical trials of atopic dermatitis	78
Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results	78
Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy	78
Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination	77
The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular	77
SCID newborn screening: What we’ve learned	75
JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition	74
Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity	74
Mild atopic dermatitis lacks systemic inflammation and shows reduced nonlesional skin abnormalities	73
Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis	73
Single-cell transcriptomics applied to emigrating cells from psoriasis elucidate pathogenic versus regulatory immune cell subsets	73
A substantial neutrophilic inflammation as regular part of severe type 2 chronic rhinosinusitis with nasal polyps	73
The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases	72
Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa	71
Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers	70
Novel hereditary angioedema linked with a heparan sulfate 3-O-sulfotransferase 6 gene mutation	70
Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria	70
Rethinking neutrophils and eosinophils in chronic rhinosinusitis	70